Oregon August 31, 2017
Good news from trial NCT02688712, for Stage II rectal cancer receiving first treatment, to illustrate why and how clinical trials shouldn't be considered something to try after everything failed.
* Chemoradiation+ Xeloda or 5-Fu + IMMUNOTHERAPY (TGFβ Type I Receptor Inhibitor LY2157299)
* Only in Providence, Oregon.
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
''The first three patients to participate in the clinical trial have shown a “dramatic response,” according to Dr. Young. One patient’s tumor completely disappeared, while the two other patients had more than a 75 percent decrease in tumor size, with equally impressive responses in the lymph nodes. ''
''The trial is open to patients with Stage 2 and higher rectal cancer who are slated to undergo the standard treatment of radiation and chemotherapy prior to surgery. The clinical trial adds an additional component to the pre-surgery radiation/chemotherapy regimen – immunotherapy. It is administered in the form of daily pills for two weeks prior to radiation and chemotherapy, and then during that treatment as well.''http://www.prweb.com/releases/2017/08/prweb14644140.htm
The trial page: https://clinicaltrials.gov/ct2/show/NCT02688712